Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria.
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; Department of Pathology, Medical University of Vienna, Vienna, Austria; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; Department of Pathology, Medical University of Vienna, Vienna, Austria; Biochemical Institute, University of Kiel, Kiel, Germany.
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; Department of Cell Biology, Charles University, Prague, Czech Republic and Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Vestec u Prahy, Czech Republic.
Visa övriga samt affilieringar
2024 (Engelska)Ingår i: Molecular Cancer, E-ISSN 1476-4598, Vol. 23, nr 1, artikel-id 114Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic drivers, the molecular programs contributing to prostate cancer progression are not fully understood.

Methods: We analyzed JUN expression in clinical prostate cancer samples across different stages and investigated its functional role in a Pten-deficient mouse model. We performed histopathological examinations, transcriptomic analyses and explored the senescence-associated secretory phenotype in the tumor microenvironment.

Results: Elevated JUN levels characterized early-stage prostate cancer and predicted improved survival in human and murine samples. Immune-phenotyping of Pten-deficient prostates revealed high accumulation of tumor-infiltrating leukocytes, particularly innate immune cells, neutrophils and macrophages as well as high levels of STAT3 activation and IL-1β production. Jun depletion in a Pten-deficient background prevented immune cell attraction which was accompanied by significant reduction of active STAT3 and IL-1β and accelerated prostate tumor growth. Comparative transcriptome profiling of prostate epithelial cells revealed a senescence-associated gene signature, upregulation of pro-inflammatory processes involved in immune cell attraction and of chemokines such as IL-1β, TNF-α, CCL3 and CCL8 in Pten-deficient prostates. Strikingly, JUN depletion reversed both the senescence-associated secretory phenotype and senescence-associated immune cell infiltration but had no impact on cell cycle arrest. As a result, JUN depletion in Pten-deficient prostates interfered with the senescence-associated immune clearance and accelerated tumor growth.

Conclusions: Our results suggest that JUN acts as tumor-suppressor and decelerates the progression of prostate cancer by transcriptional regulation of senescence- and inflammation-associated genes. This study opens avenues for novel treatment strategies that could impede disease progression and improve patient outcomes. Graphical Abstract: (Figure presented.).

Ort, förlag, år, upplaga, sidor
BioMed Central (BMC), 2024. Vol. 23, nr 1, artikel-id 114
Nyckelord [en]
AP-1 transcription factors, Immune infiltration, JUN, Prostate cancer, SASP, Senescence
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-225946DOI: 10.1186/s12943-024-02022-xISI: 001234826100001PubMedID: 38811984Scopus ID: 2-s2.0-85194834139OAI: oai:DiVA.org:umu-225946DiVA, id: diva2:1868919
Forskningsfinansiär
EU, Horisont 2020, 675712Tillgänglig från: 2024-06-12 Skapad: 2024-06-12 Senast uppdaterad: 2024-10-21Bibliografiskt granskad

Open Access i DiVA

fulltext(4335 kB)87 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 4335 kBChecksumma SHA-512
5c8ea818e2014852af4099ddea116f417efae2b78f3d60f3b68dbdeaee235050779918a4de4d0652af0a3ed056ee2bab778e44b5ca4ddb43ab0a11c7d295d63d
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Persson, Jenny L.Kenner, Lukas

Sök vidare i DiVA

Av författaren/redaktören
Persson, Jenny L.Kenner, Lukas
Av organisationen
Institutionen för molekylärbiologi (Medicinska fakulteten)
I samma tidskrift
Molecular Cancer
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 87 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 420 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf